Developability and CMC at Antibody Engineering 2026

Dec 13–16, 2026 San Diego, CA ~900 attendees Website

33 organizations at Antibody Engineering 2026 present work in developability & CMC: 20 suppliers and service providers, 11 drug developers and 2 academic, government and non-profit bodies. Between them they bring 36 presentations to the program. Most represented: Xencor (4 on the program), Regeneron (3 on the program), Amgen (2 on the program). 24 of them have their own page in this guide. As of Sep 26, 2026.

All 153 organizations at Antibody Engineering 2026 →

Showing 1–14 of 33 organizations

Organization	Antibody Engineering 2026 Attendance
Xencor Pasadena, CA
xencor.com Biotech Develops engineered antibodies using its XmAb Fc and bispecific technologies, for cancer and autoimmune diseases.	Talk Sun Dec 13 1:00pm–1:15pm Co-Chairs' Remarks: From Discovery to IND: What Matters Most and How to Get it Right Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Amgen Talk Sun Dec 13 4:15pm–5:00pm Moderated Panel Discussion with Session Speakers Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Amgen Talk Mon Dec 14 8:00am–8:05am Co-Chairs' Welcome and Opening Remarks Keynote Presentations - Livestream · with Gyes Talk Mon Dec 14 10:55am–11:30am Jim Huston Science Talent Award and Presentation: Keynote Presentations - Livestream · with Dana-Farber Cancer Institute Talk Wed Dec 16 8:10am–8:15am Co-Chairs’ Remarks Track 2: Engineering Antibody Interfaces: Unlocking New Biology · with Dualitas Therapeutics Talk Wed Dec 16 9:15am–9:45am XenLock™ Fab domains for controlled heavy-light chain pairing in native-like 1+1 bispecific antibodies with extended half-life Redesigned antibody arms that pair only with their intended partner, used to build two-target antibodies that last longer in blood. Bispecifics & multispecifics
Regeneron Tarrytown, NY
regeneron.com Large pharma Biotechnology company that discovers, develops and markets antibody medicines, including bispecific antibodies, using its VelocImmune mouse platform.	Talk Sun Dec 13 3:45pm–4:15pm From Molecule Design to Approved Regimens: A Clinical Pharmacology Perspective on Dose Selection for Next-Generation Biologics How measurements of drug levels and effects in the body guide the first human dose and the final approved dosing schedule. Talk Mon Dec 14 5:15pm–5:45pm Targeting IgE Responses Track 2: Engineering Solutions for Accessing Difficult Targets Beyond oncology Talk Wed Dec 16 8:10am–8:15am Co-Chairs’ Remarks Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs · with Rondo Therapeutics
Amgen Thousand Oaks, CA
amgen.com Large pharma Global biopharmaceutical company developing and manufacturing biologic medicines, including bispecific T-cell engagers.	Talk Sun Dec 13 1:00pm–1:15pm Co-Chairs' Remarks: From Discovery to IND: What Matters Most and How to Get it Right Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Xencor Talk Sun Dec 13 1:15pm–1:45pm Developability-Guided Generative Biology for Therapeutic Protein Engineering Designing new therapeutic proteins by computer while checking from the start that they can be made and purified. AI & computational design Talk Sun Dec 13 4:15pm–5:00pm Moderated Panel Discussion with Session Speakers Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Xencor
Johnson & Johnson New Brunswick, NJ
jnj.com Large pharma Healthcare company whose Innovative Medicine segment develops antibodies, bispecifics and other medicines.	Talk Sun Dec 13 2:15pm–2:45pm Format Matters: Biophysical Characterization and Developability of Complex Biotherapeutics How a molecule's overall shape changes whether it can be made into a drug, across many measured antibody formats. Talk Tue Dec 15 8:10am–8:15am Co-Chairs’ Remarks Track 1: Advanced In Vivo Approaches to Antibody Discovery · with Genentech
University of Michigan Ann Arbor, MI
umich.edu Academic Public research university in Ann Arbor, Michigan.	Talk Sun Dec 13 1:00pm–1:15pm Co-Chairs’ Remarks- Engineering Considerations for Candidate Selection and Developability Workshop 2: Engineering Considerations for Candidate Selection and Developability · with Atlas Venture NewCo Talk Tue Dec 15 3:00pm–3:30pm Dual-targeted Oligoshuttles Mediate Efficient Reduction of Neuronal Gene Expression after Peripheral Administration Antibodies that grab two receptors to cross into the brain and deliver gene-silencing strands into nerve cells. Bispecifics & multispecifics
Zymeworks
zymeworks.com Biotech Develops multispecific antibody therapeutics and antibody–drug conjugates using its Azymetric bispecific and other protein engineering platforms.	Talk Sun Dec 13 1:45pm–2:15pm Engineering Conditional Co-stimulation: Key Considerations for Developing Next-Generation T Cell Engagers What to get right, from target choice to safety testing, when building T-cell-recruiting antibodies with a built-in second signal. Bispecifics & multispecifics Talk Wed Dec 16 8:45am–9:15am Engineering Trispecific T Cell Engagers (TriTCEs) For Optimal Activity and Developability Antibodies that bind three things at once to give T cells an extra activating signal inside solid tumors. Developability & CMC
Twist Bioscience South San Francisco, CA
twistbioscience.com Reagents & consumablesEvent partner Synthetic DNA company whose biopharma unit provides antibody libraries and antibody discovery and optimization services.	Booth Exhibiting at Booth 201 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 12:15pm–1:15pm Engineering for Better Bispecifics: Introducing the B-Body® Platform A two-target antibody design meant to assemble reliably, avoiding low yields and hard purification when production scales up. Bispecifics & multispecificsDevelopability & CMC Talk Wed Dec 16 7:30am–8:00am A High-Throughput Ecosystem to Power AI-Driven Antibody Discovery Building large custom variant libraries so computer-designed antibodies can be made and tested in the lab within weeks. Antibody discoveryAI & computational design
Primrose Bio San Diego, CA
primrosebio.com CRO & CDMOSilver sponsor Licenses its Pseudomonas-based Pfenex expression technology and provides strain engineering to take protein therapeutics from sequence to a GMP-ready process.	Booth Exhibiting at Booth 305 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Tue Dec 15 12:05pm–12:35pm From Hit Selection to Functional Testing: Reducing Expression Bottlenecks in Antibody Discovery Producing antibody fragments earlier in a different host organism, so more hits can actually be purified and tested. Antibody discoveryDevelopability & CMC
Thomson Instrument Company Oceanside, CA
htslabs.com Reagents & consumablesSilver sponsor Supplies Optimum Growth shake flasks, well plates and filter vials for transient and stable cell culture and sample preparation.	Booth Exhibiting at Booth 218 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 12:15pm–1:15pm Tips and Tricks in Speeding up Transient HEK293 and Transient/Stable CHO from 96 Well, 24 Well, 6 Well, 125mL-7L Optimum Growth Flasks Practical ways to get more protein out of small-volume cell cultures, from well plates up to multi-liter flasks. Developability & CMC
Adimab Lebanon, NH
adimab.com Discovery platforms Discovers and optimizes antibodies for drug developers using a yeast-based display platform, through partnerships.	Talk Sun Dec 13 3:45pm–4:15pm Antibody Polyspecificity Profiling Workshop 2: Engineering Considerations for Candidate Selection and Developability
AV Atlas Venture NewCo
	Talk Sun Dec 13 1:00pm–1:15pm Co-Chairs’ Remarks- Engineering Considerations for Candidate Selection and Developability Workshop 2: Engineering Considerations for Candidate Selection and Developability · with University of Michigan
EMD Serono Rockland, MA
emdserono.com Large pharma US and Canadian healthcare business of Merck KGaA, Darmstadt, developing medicines in oncology, neurology and fertility.	Talk Sun Dec 13 1:45pm–2:15pm A Combined Computational and Experimental Cascade for Variable Domain Assessment and Optimization Towards Developable Multispecific Antibodies Splitting a multi-target antibody into its binding pieces and improving each one without losing target binding. AI & computational design
EpiVax Providence, RI
epivax.com Software & AI Offers in silico immunogenicity screening tools and matching human immune assays for antibody and protein therapeutics.	Panel Sun Dec 13 4:15pm–4:45pm Beyond Sequence Prediction: Integrating AI-Driven In Silico Analysis with Human Immune Assays for Antibody Engineering Combining predictions of immune reactions against a drug with tests on human blood cells to design safer antibodies. AI & computational design
Inhibrx San Diego, CA
inhibrx.com Biotech Develops engineered multivalent antibody therapeutics, including a tetravalent DR5 agonist for cancer.	Talk Sun Dec 13 3:15pm–3:45pm Ozekibart: A Tetravalent Antibody Precisely Engineered for Optimal DR5 Agonism and Safety An antibody with four arms that clusters a cell-death receptor just enough to kill tumor cells without added toxicity. Protein engineering